These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3441327)

  • 41. [89Sr Therapy for pain relief in patients with bone metastases].
    Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
    Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 89Strontium therapy of bone metastases of carcinoma of the prostatic gland.
    Correns HJ; Mebel M; Buchali K; Schnorr D; Seidel C; Mitterlechner E
    Eur J Nucl Med; 1979 Feb; 4(1):33-5. PubMed ID: 499225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Nuclear medicine therapy of bone metastases].
    Kimmig B; Hermann HJ; Kober B
    Rontgenblatter; 1983 Jul; 36(7):216-9. PubMed ID: 6622951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
    Altman GB; Lee CA
    Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases.
    Papatheofanis FJ
    Br J Radiol; 1997 Jun; 70(834):594-8. PubMed ID: 9227252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
    Zhao W; Deng H; Jie P; Qing C; Zhang X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
    Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strontium and samarium therapy for bone metastases from prostate carcinoma.
    Dickie GJ; Macfarlane D
    Australas Radiol; 1999 Nov; 43(4):476-9. PubMed ID: 10901963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radionuclide-targeted therapy for the management of metastatic bone pain.
    Ackery D; Yardley J
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A direct measurement of strontium-89 activity in bone metastases.
    Ben-Josef E; Maughan RL; Vasan S; Porter AT
    Nucl Med Commun; 1995 Jun; 16(6):452-6. PubMed ID: 7675358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Imaging of strontium-89 uptake with bremsstrahlung using NaI scintillation camera].
    Narita H; Uchiyama M; Ooshita T; Hirase K; Makino M; Mori Y; Sekine H; Kawakami K
    Kaku Igaku; 1996 Nov; 33(11):1207-12. PubMed ID: 8986059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer.
    Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA
    Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Strontium 89 in the treatment of bony metastases.
    Porter AT; Ben-Josef E
    Important Adv Oncol; 1995; ():87-94. PubMed ID: 7545646
    [No Abstract]   [Full Text] [Related]  

  • 55. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
    Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Papapoulos SE; Hamdy NA
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer.
    Quilty PM; Kirk D; Bolger JJ; Dearnaley DP; Lewington VJ; Mason MD; Reed NS; Russell JM; Yardley J
    Radiother Oncol; 1994 Apr; 31(1):33-40. PubMed ID: 7518932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic radionuclide therapy in pain palliation.
    Liepe K; Runge R; Kotzerke J
    Am J Hosp Palliat Care; 2005; 22(6):457-64. PubMed ID: 16323716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
    Ouyang W; Liu JH; Liu WY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):390-1. PubMed ID: 17426002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.